Optimizing novel agent combination therapy for previously untreated, high risk chronic lymphocytic leukemia

优化针对先前未治疗的高风险慢性淋巴细胞白血病的新药联合疗法

• 批准号: 10522611
• 负责人: MATTHEW S DAVIDS
• 金额: $ 42.14万
• 依托单位: DANA-FARBER CANCER INST
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-15 至 2027-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10522611
• 关键词: Achievement; Agammaglobulinaemia tyrosine kinase; Apoptotic; B lymphoid malignancy; B-Cell Leukemia; BCL2L1 gene; Biological Assay; Chronic Lymphocytic Leukemia; Clinical; Clinical Trials; Combined Modality Therapy; Data; Dependence; Disease; Elderly; Elements; Family member; Flow Cytometry; Future; Generations; Genes; Genomics; Genotype; Goals; Grant; Head; Heme; In complete remission; Karyotype; Laboratories; Laboratory Study; MCL1 gene; Mitochondria; Monoclonal Antibody CD20; Multi-Institutional Clinical Trial; Mutation; Patient-Focused Outcomes; Patients; Pattern; Pharmaceutical Preparations; Phase; Phase II Clinical Trials; Phenotype; Phosphorylation; Phosphotransferases; Population; Principal Investigator; Progression-Free Survivals; Protein Family; Protein Phosphatase 2A Regulatory Subunit PR53; Proteins; Regimen; Research Personnel; Residual Neoplasm; Resistance; Resistance development; Rest; Risk; Safety; Sampling; Sampling Studies; Somatic Mutation; Subgroup; TP53 gene; Technology; Testing; Therapeutic; Therapy trial; Time; Toxic effect; Triplet Multiple Birth; Tyrosine Kinase Inhibitor; anti-CD20; base; chronic lymphocytic leukemia cell; clinical predictors; comorbidity; design; experience; genomic predictors; high risk; individualized medicine; inhibitor; innovation; leukemia/lymphoma; next generation sequencing; novel; optimal treatments; personalized decision; predicting response; protein B; resistance mechanism; response; response biomarker; standard of care; survival prediction; targeted agent; therapy duration; tositumomab; treatment duration; treatment response

SUMMARY/ABSTRACT Patients with high-risk TP53 aberrant chronic lymphocytic leukemia (CLL) have a shorter survival than other CLL patients. We previously found that the BTK inhibitor acalabrutinib (A) and the BCL-2 inhibitor venetoclax (V) are highly effective at killing CLL cells ex vivo. We developed AVO, a new time-limited triplet combination regimen combining AV with an anti-CD20 antibody obinutuzumab (O). The AVO clinical trial and correlative laboratory studies on primary samples from this trial comprise the key elements of this project. The first aim of the project is to determine the efficacy of the AVO combination regimen in patients with previously untreated TP53 aberrant CLL. We hypothesize that AVO will be a highly efficacious and well- tolerated novel agent triplet regimen, with individualized therapy duration guided by achievement of undetectable minimal residual disease (uMRD). This hypothesis will be tested through determining the proportion of patients who achieve complete response (CR) with uMRD, as well as characterizing the safety of the regimen, in an investigator-initiated, phase 2, multicenter clinical trial of AVO in patients with previously untreated CLL. The second aim of the project is to assess whether MRD clonal dynamics, pre-treatment mitochondrial priming, or genomic complexity predict clinical response to AVO. We will utilize a next-generation sequencing (NGS) based technology, Adaptive ClonoSEQ, to assess whether MRD clonal dynamics with this assay can more accurately predict survival and guide treatment duration decisions compared with conventional flow cytometry- based MRD. Through functional interrogation of CLL cell mitochondria by BH3 profiling, we hypothesize that patients with higher levels of mitochondrial priming at baseline and/or early on treatment will achieve a higher rate of CR with uMRD on AVO. Genomic predictors of response will also be assessed through stimulated karyotype and mutational profiling with a 95-gene NGS ‘rapid heme panel’ (RHP). The third aim of the project is to elucidate mechanisms of resistance to AVO, including acquired somatic mutations, modulation in mitochondrial priming, alterations in phosphorylation, and kinase activity. We will use RHP to evaluate the pattern of somatic mutations as they develop. We will also evaluate whether CLL cells that are typically dependent on BCL-2 at baseline will develop alternative survival dependencies on other anti- apoptotic proteins at progression. In addition, we will assess whether BCL-2 family protein phosphorylation may represent a functional resistance mechanism, and whether PP2A activators can help reverse this and thereby restore sensitivity. And we will use high-throughput kinase activity mapping (HT-KAM) to identify which kinases are activated in resistant patients to identify new, potentially therapeutically actionable targets. Elucidating resistance mechanisms will inform the design of future novel agent combination therapy trials, with the goal of decreasing the risk of acquired therapy resistance in CLL and eventually other B cell malignancies.

摘要/摘要 高危突变型慢性淋巴细胞白血病(CLL)患者的生存期比其他患者短 慢性淋巴细胞性白血病患者。我们之前发现BTK抑制剂阿卡拉布替尼(A)和bcl2抑制剂ventoclax (V)在体外高效地杀伤CLL细胞。我们开发了AVO，一种新的限时三胞胎组合 联合用抗CD20抗体的联合方案(O)。脑动静脉阻塞的临床试验及相关研究 对这项试验的初级样本进行的实验室研究构成了这一项目的关键要素。 该项目的第一个目标是确定AVO联合方案对慢性阻塞性肺疾病患者的疗效。 先前未经治疗的TP53异常的CLL。我们假设AVO将是一种高效和良好的- 耐受性新的药物三联方案，个体化治疗持续时间由以下成就指导 无法检测到的微小残留病(UMRD)。这一假设将通过确定 用uMRD获得完全缓解(CR)的患者比例，以及 该方案在研究人员发起的AVO患者的2期多中心临床试验中 未经治疗的慢性淋巴细胞性白血病。 该项目的第二个目标是评估MRD克隆动力学、治疗前线粒体启动、 或基因组复杂性预测对AVO的临床反应。我们将利用下一代测序(NGS) 基于自适应ClonoSEQ技术，评估使用该检测方法的MRD克隆动力学是否可以更多 与传统的流式细胞术相比，准确地预测存活率并指导治疗持续时间决定- 基于MRD的。通过BH3图谱对CLL细胞线粒体的功能询问，我们推测 在基线和/或治疗早期线粒体启动水平较高的患者将获得更高的 AVO对uMRD的CR率。反应的基因组预测因子也将通过刺激进行评估 用95基因NGS‘快速血红素小组’(RHP)进行核型和突变分析。 该项目的第三个目标是阐明对AVO的抗性机制，包括获得性体细胞 突变，线粒体启动的调节，磷酸化的改变，以及激酶活性。我们将使用 RHP来评估发育过程中的体细胞突变模式。我们还将评估CLL细胞是否 在基线上通常依赖于bcl-2的人将对其他抗- 正在进行中的细胞凋亡蛋白。此外，我们还将评估bcl2家族蛋白的磷酸化 可能代表了一种功能抵抗机制，以及PP2A激动剂是否可以帮助逆转这种情况并 从而恢复敏感度。我们将使用高通量激酶活性图谱(HT-KAM)来识别哪些 在耐药患者中激活激酶，以确定新的、潜在的治疗可操作的靶点。 阐明耐药机制将为未来新型药物联合治疗试验的设计提供信息， 目标是降低慢性淋巴细胞性白血病和最终其他B细胞恶性肿瘤获得性治疗耐药的风险。